Who makes NEWSTATIN TS?

NEWSTATIN TS is developed by Hyo-Soo Kim.

What development phase is NEWSTATIN TS in?

NEWSTATIN TS is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

NEWSTATIN TS

Hyo-Soo Kim · FDA-approved active Small molecule Quality 2/100

NEWSTATIN TS, marketed by Hyo-Soo Kim, is a statin with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current marketed status. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.

At a glance

Generic name	NEWSTATIN TS
Also known as	Newstatin TS 40/5/10mg
Sponsor	Hyo-Soo Kim
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NEWSTATIN TS CI brief — competitive landscape report
NEWSTATIN TS updates RSS · CI watch RSS
Hyo-Soo Kim portfolio CI